Single-dose intravesical Epodyl after TUR of Ta TCC bladder carcinoma
Article
- 27 Downloads
- 16 Citations
Summary
Between 1973 and 1979, 130 patients with pTa noninvasive bladder carcinoma were treated either by TUR plus intravesical chemotherapy with a single dose of Epodyl on the following day (60 patients), or by TUR only (70 patients). There was no significant difference between the two treatment groups as to time until first recurrence. However, the recurrence rate with Epodyl was significantly lower than that with no adjuvant treatment (P<0.01). The incidence of increase in T-category was lower among patients who received Epodyl (P<0.01). Thus single dose intravesical chemotherapy following TUR appeared to be beneficial.
Keywords
Public Health Carcinoma Treatment Group Single Dose Recurrence Rate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Lange PH (1982) Marker proteins as a guide in clinical management of genitourinary cancer. In: Paulson DF (ed) Genitourinary cancer I. Nijhoff, The Hague, pp 45–72Google Scholar
- 2.Coon JS (1982) Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol 77:692–699Google Scholar
- 3.Sandberg AA (1982) Chromosomes in bladder cancer. In: Bonney WW, Prout GR (ed) Bladder cancer. Williams & Wilkins, Baltimore, pp 81–94Google Scholar
- 4.Dalesio O, Schulman CC, Sylvester R, de Pauw M, Robinson M, Denis L, Smith P, Viggiano G, EORTC GU Group (1983) Prognostic factors in superficial bladder tumors: a study of the EORT Genito-Urinary Tract Cancer Cooperative Group. J Urol (in press)Google Scholar
- 5.Oyasu R, Hopp ML (1974) The etiology of cancer of the bladder. Surg Gynecol Obstet 138:97–108Google Scholar
- 6.Weyrauch HM, Crossfield JH (1962) Dissemination of bladder neoplasms by endoscopic electroresection. J Urol 87:391–397Google Scholar
- 7.Weldon TE, Soloway MS (1975) Susceptibility of urothelium to neoplastic cellular implantation. Urology 5:824–827Google Scholar
- 8.Page BH, Levison VB, Curwen MP (1978) The site of recurrence of noninfiltrating bladder tumors. Br J Urol 50:237–242Google Scholar
- 9.Varkarakis MJ, Gaete J, Moore RH, Murphy GP (1974) Superficial bladder tumor, aspects of clinical progression. Urology 4:414–420Google Scholar
- 10.Althausen AF, Prout GR, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116:575–580Google Scholar
- 11.Cooper TP, Wheele RF, Correa RJ, Gibbons RP, Mason JT, Cummings KB (1977) Random mucosal biopsies in the evaluation of patients with carcinoma of the bladder. J Urol 117:46–48Google Scholar
- 12.Soloway MS, Murphy W, Rao MK, Cox C (1978) Serial multiplesite biopsies in patients with bladder cancer. J Urol 120:57–59Google Scholar
- 13.Abbassian A, Wallace DM (1966) Intracavitary chemotherapy of diffuse non-infiltrating papillary carcinoma of the bladder. J Urol 96:461–465Google Scholar
- 14.Riddle PR (1973) The management of superficial bladder tumors with intravesical Epodyl. Br J Urol 45:84–87Google Scholar
- 15.Riddle PR, Khan O, Fitzpatrick JM, Oliver RT (1982) Prognostic factors influencing survival of patients receiving intravesical Epodyl. J Urol 127:430–432Google Scholar
- 16.van Wijk JA (1975) De invloed van Etoglucide (Epodyl) op blaaspoliepen. Ned Tijdschr Geneeskd 119:898Google Scholar
- 17.Robinson MRG, Shetty MB, Richards B, Bastable J, Glashan RW, Smith PH (1977) Intravesical Epodyl in the management of bladder tumors: combined experience of the Yorkshire urological cancer research group. J Urol 118:972–973Google Scholar
- 18.Smith JM, Lane V, O'Flynn JD (1978) Epodyl in management of noninvasive vesical neoplasms. Urology 11:474–477Google Scholar
- 19.Popa G, Peters HJ, Potempa J (1978) Konservative Behandlung von Harnblasenpapillomen mit Epodyl. Therapiewoche 28:2013–2014Google Scholar
- 20.Colleen S, Hellsten AES, Lindholm CE (1980) Intracavitary Epodyl® for multiple non-invasive highly differentiated bladder tumors. Scand J Urol Nephrol 14:43–45Google Scholar
- 21.UICC (1978) TNM classification of malignant tumors, 3rd edn. Harmer MH (ed). Union Internationale Contre le Cancer, GenevaGoogle Scholar
- 22.Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW (1976) Single dose intravesical Thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48:55–59Google Scholar
- 23.Gavrell GJ, Lewis RW, Meehan WL, Leblanc GA (1978) Intravesical Thiotepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120:410–411Google Scholar
- 24.Abrams PH, Choa RG, Gaches CGC, Ashken MH, Green NA (1981) A controlled trial of single dose intravesical Adriamycin in superficial bladder tumors. Br J Urol 53:585–587Google Scholar
- 25.Zincke H, Utz DC, Leary FJ, Myers RP, Rochester MN (1981) The influence of intravesical Thiotepa and Doxorubicin HCL at time of transurethral resection (TUR) of bladder tumors (BT) on tumor recurrence. Proceedings of the American Urologic Association, Boston, May 1981 (abstr no 580)Google Scholar
- 26.Veenema RJ (1978) Editorial comment. J Urol 120:411Google Scholar
- 27.Soloway MS, Murphy WM (1979) Experimental chemotherapy of bladder cancer — systemic and intravesical. Semin Oncol 6:166–183Google Scholar
Copyright information
© Springer-Verlag 1983